Alan Walshe Thanks PPTA on Behalf of Plasma Donors And Patients Who Rely on PDMPs
Alan Walshe, Senior Vice President, Head of Global Commercial Strategy for Plasma Derived Therapies at Takeda, reposted from Anita Brikman on LinkedIn:
”This year’s Plasma Protein Forum, taking place in Washington DC, is tackling the most urgent issues facing Plasma-Derived Medicinal Products (PDMPs) including growing patient need, plasma donor health and the vital importance of partnering with regulators and other stakeholders.
Thank you Plasma Protein Therapeutics Association (PPTA) for your important work on behalf of plasma donors and patients who rely on PDMPs.”
Quoting Anita Brikman‘s post:
”Day one of the Plasma Protein Forum set a powerful tone for collaboration, innovation, and impact across the plasma community.
Plasma Protein Therapeutics Association (PPTA) Global Executive Board Chair Giles Platford began the day by reminding attendees of the importance of science-driven progress and global partnership.
Dr. Namandje Bumpus continued that discussion by delivering a collaborative keynote on regulatory excellence.
Sessions then moved to thought-provoking examinations on trade, donor health, state policy, and innovation.
Each session underscored the industry’s shared commitment to donors and patients.
A special thank you to all speakers, moderators, and sponsors who made today’s sessions and networking moments so engaging.
I am excited to see what tomorrow will bring at PPF2025.”
More from PPF2025 featured in Hemostasis Today.
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 17, 2025, 08:33Hossam El Benawi to Present Latest Mayo Clinic Insights on Left Ventricular Thrombus at AHA 2026
-
Oct 17, 2025, 08:32Brian O Mahony Invites You to Irish Haemophilia Society Webinar Series
-
Oct 17, 2025, 08:30Thomas Reiser Invites You to Take A Survey on AI and Machine Learning From ISTH
-
Oct 17, 2025, 09:00Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
-
Oct 17, 2025, 08:41Review of Community-Based Stroke Rehabilitation in LMICs from Dominique Cadilhac's Team
-
Oct 16, 2025, 04:43Michael Makris Invites You to The Research Recap on FEIBA Use in Patients on Emicizumab
-
Oct 16, 2025, 04:41Suhasini Sil on Impact of AMBM Red Cell Transfusions in Improving Transfusion Outcomes
-
Oct 16, 2025, 04:37Hinde El Otmani's Team Explores Plasmin-Mediated Proteolysis of von Willebrand Factor in Acutely Ill Patients
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success
-
Oct 16, 2025, 04:44Giles Platford Discusses Strengthening the Plasma Ecosystem for Patients Worldwide at PPF2025
-
Oct 16, 2025, 04:27Ranjeet Ajmani: Southeast Asia - 25% of The Global Population Contributes Less than 2% of The Global Plasma Supply
-
Oct 15, 2025, 05:59Courtney Lawrence: I've Got A Place at American Red Cross for You!